A “Game Changer” For The High-Risk MDS Patient Population

Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions. In Vivo questions the current progress of their lead asset BEXMAB and its potential moving forward.

Episode metadata supplied by the publisher feed · Published Jan 17, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

A “Game Changer” For The High-Risk MDS Patient Population

0:00 13:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 13 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on January 17, 2025.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!